CD274 and non-small cell lung carcinoma: Additionally, we noted that the above downstream targets presented remarkable interactions with circadian rhythm and immune activation pathways (like allograft rejection, T cell receptor signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, inflammatory mediator regulation of TRP channels, and inflammatory bowel disease) as well as carcinogenic pathways (like transcriptional misregulation in cancer, FoxO signaling pathway, non-small cell lung cancer, MAPK signaling pathway, AMPK signaling pathway, Rap1 signaling pathway, and apoptosis; Figure 7(b) and Table 3).